Abstract
Unprecedented progress continues to be made in the treatment strategies for the myelodysplastic syndromes (MDS). This review provides an introduction to DNA methyltransferase inhibitors. These agents include 5-azacytidine (azacitidine; AZA) and 5-aza-2’- deoxycytidine (decitabine; DAC). In particular, AZA was shown for the first time to significantly prolong the life expectancy of high-risk MDS patients in international multicenter clinical studies. The selection of responders and assessment of the long-term efficacy warrant further study.
Keywords: MDS, DNA hypomethylation, epigenetic therapy, DNA methyltransferase inhibitors, azacitidine, decitabine, long-term efficacy, hematopoietic stem cell disorders, solid tumors, cytotoxic
Current Pharmaceutical Design
Title:Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes
Volume: 18 Issue: 22
Author(s): Kaoru Tohyama
Affiliation:
Keywords: MDS, DNA hypomethylation, epigenetic therapy, DNA methyltransferase inhibitors, azacitidine, decitabine, long-term efficacy, hematopoietic stem cell disorders, solid tumors, cytotoxic
Abstract: Unprecedented progress continues to be made in the treatment strategies for the myelodysplastic syndromes (MDS). This review provides an introduction to DNA methyltransferase inhibitors. These agents include 5-azacytidine (azacitidine; AZA) and 5-aza-2’- deoxycytidine (decitabine; DAC). In particular, AZA was shown for the first time to significantly prolong the life expectancy of high-risk MDS patients in international multicenter clinical studies. The selection of responders and assessment of the long-term efficacy warrant further study.
Export Options
About this article
Cite this article as:
Tohyama Kaoru, Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023190
DOI https://dx.doi.org/10.2174/1381612811209023190 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MYC-mediated Synthetic Lethality for Treatment of Hematological Malignancies
Current Cancer Drug Targets Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Current Cancer Drug Targets Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology The Role of FLT3 Kinase as an AML Therapy Target
Current Pharmaceutical Design Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Perspectives in Medicinal Chemistry: DNA Methylation and Demethylation Mechanisms as Therapeutic Targets?
Current Topics in Medicinal Chemistry KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives
Current Molecular Medicine Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Role of Nutrients and Phyto-compounds in the Modulation of Antimicrobial Resistance
Current Drug Metabolism Editorial (Thematic Issue: Combined Cancer Therapy)
Current Pharmaceutical Design Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry 5q- syndrome
Current Pharmaceutical Design Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Transient Receptor Potential Channels in Human Platelets: Expression and Functional Role
Current Molecular Medicine Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design